Bal Pharma Limited (BALPHARMA.BO)
INR 111.73
(1.87%)
INR 111.73
(1.87%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 233.9 Million INR | 21.07% |
| 2022 | 177.23 Million INR | 18.81% |
| 2021 | 149.17 Million INR | 6.07% |
| 2020 | 140.64 Million INR | 352.2% |
| 2019 | -55.76 Million INR | -170.03% |
| 2018 | 79.63 Million INR | 11.42% |
| 2017 | 71.46 Million INR | -16.82% |
| 2016 | 85.91 Million INR | 6.52% |
| 2015 | 80.65 Million INR | -17.93% |
| 2014 | 98.27 Million INR | -21.31% |
| 2013 | 124.88 Million INR | 0.66% |
| 2012 | 124.06 Million INR | 26.12% |
| 2011 | 98.37 Million INR | 33.81% |
| 2010 | 73.51 Million INR | 481.28% |
| 2009 | 12.64 Million INR | -86.42% |
| 2008 | 93.14 Million INR | 27.95% |
| 2007 | 72.79 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 40.37 Million INR | -45.71% |
| 2023 Q1 | 39.1 Million INR | -35.65% |
| 2023 Q2 | 52.78 Million INR | 34.99% |
| 2023 Q3 | 49.26 Million INR | -6.66% |
| 2023 Q4 | 74.36 Million INR | 50.94% |
| 2023 FY | 214.56 Million INR | 21.07% |
| 2022 FY | 177.23 Million INR | 18.81% |
| 2022 Q4 | 60.76 Million INR | 64.07% |
| 2022 Q3 | 37.03 Million INR | 8.73% |
| 2022 Q2 | 34.06 Million INR | 21.29% |
| 2022 Q1 | 28.08 Million INR | 173.97% |
| 2021 Q4 | 10.25 Million INR | -74.41% |
| 2021 Q3 | 40.05 Million INR | -2.59% |
| 2021 Q2 | 41.11 Million INR | -22.34% |
| 2021 FY | 149.17 Million INR | 6.07% |
| 2021 Q1 | 52.94 Million INR | 81.84% |
| 2020 Q2 | 49.9 Million INR | 48.63% |
| 2020 FY | 140.64 Million INR | 352.2% |
| 2020 Q3 | 40.89 Million INR | -18.05% |
| 2020 Q4 | 29.11 Million INR | -28.81% |
| 2020 Q1 | 33.57 Million INR | 196.1% |
| 2019 FY | -55.76 Million INR | -170.03% |
| 2019 Q2 | 5.06 Million INR | 0.6% |
| 2019 Q1 | 5.03 Million INR | -58.26% |
| 2019 Q3 | -3.04 Million INR | -160.22% |
| 2019 Q4 | -34.94 Million INR | -1046.73% |
| 2018 Q4 | 12.05 Million INR | -62.17% |
| 2018 Q2 | 30.3 Million INR | -4.87% |
| 2018 FY | 79.63 Million INR | 11.42% |
| 2018 Q1 | 31.85 Million INR | -9.96% |
| 2018 Q3 | 31.85 Million INR | 5.12% |
| 2017 FY | 71.46 Million INR | -16.82% |
| 2017 Q4 | 35.37 Million INR | 0.0% |
| 2016 Q3 | 23.04 Million INR | -45.1% |
| 2016 FY | 85.91 Million INR | 6.52% |
| 2016 Q4 | 17.43 Million INR | -24.34% |
| 2016 Q2 | 41.97 Million INR | 61.48% |
| 2016 Q1 | 25.99 Million INR | 1542.62% |
| 2015 Q4 | -1.8 Million INR | -104.78% |
| 2015 FY | 80.65 Million INR | -17.93% |
| 2015 Q1 | -1.8 Million INR | -125.79% |
| 2015 Q2 | 38.09 Million INR | 2214.26% |
| 2015 Q3 | 37.66 Million INR | -1.13% |
| 2014 Q1 | 28.83 Million INR | -14.97% |
| 2014 Q4 | 6.98 Million INR | -73.27% |
| 2014 Q3 | 26.13 Million INR | -28.08% |
| 2014 FY | 98.27 Million INR | -21.31% |
| 2014 Q2 | 36.34 Million INR | 26.06% |
| 2013 Q1 | 29.03 Million INR | -26.36% |
| 2013 Q4 | 33.9 Million INR | -1.33% |
| 2013 FY | 124.88 Million INR | 0.66% |
| 2013 Q2 | 34.07 Million INR | 17.35% |
| 2013 Q3 | 34.36 Million INR | 0.86% |
| 2012 Q2 | 31.57 Million INR | 55.15% |
| 2012 Q1 | 20.35 Million INR | -36.17% |
| 2012 Q3 | 32.81 Million INR | 3.93% |
| 2012 Q4 | 39.42 Million INR | 20.13% |
| 2012 FY | 124.06 Million INR | 26.12% |
| 2011 Q3 | 22.47 Million INR | -10.22% |
| 2011 Q4 | 31.88 Million INR | 41.89% |
| 2011 FY | 98.37 Million INR | 33.81% |
| 2011 Q2 | 25.02 Million INR | 0.0% |
| 2010 FY | 73.51 Million INR | 481.28% |
| 2009 FY | 12.64 Million INR | -86.42% |
| 2008 FY | 93.14 Million INR | 27.95% |
| 2007 FY | 72.79 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 95.938% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 99.446% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 97.395% |
| Granules India Limited | 6.81 Billion INR | 96.569% |
| Indoco Remedies Limited | 1.29 Billion INR | 81.903% |
| Achyut Healthcare Limited | 4.43 Million INR | -5170.595% |
| Ajanta Pharma Limited | 19.67 Billion INR | 98.811% |
| Alkem Laboratories Limited | 19.46 Billion INR | 98.798% |
| Alpa Laboratories Limited | 184.49 Million INR | -26.782% |
| Brooks Laboratories Limited | 14.44 Million INR | -1519.868% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | 86.381% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | 80.998% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 99.655% |
| Eris Lifesciences Limited | 5.18 Billion INR | 95.486% |
| FDC Limited | 2.98 Billion INR | 92.167% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 96.403% |
| Gufic Biosciences Limited | 1.32 Billion INR | 82.412% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 94.709% |
| Ipca Laboratories Limited | 7.98 Billion INR | 97.069% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | 53.967% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 253.931% |
| Lasa Supergenerics Limited | -458 Million INR | 151.071% |
| Laurus Labs Limited | 3.94 Billion INR | 94.076% |
| Lupin Limited | 28.04 Billion INR | 99.166% |
| Mankind Pharma Limited | 21.51 Billion INR | 98.913% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -133.209% |
| Megasoft Limited | -121.1 Million INR | 293.147% |
| NATCO Pharma Limited | 25.96 Billion INR | 99.099% |
| Piramal Pharma Limited | 4.55 Billion INR | 94.867% |
| RPG Life Sciences Limited | 2.29 Billion INR | 89.796% |
| Sigachi Industries Limited | 1.47 Billion INR | 84.13% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 99.776% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 94.923% |
| Syncom Formulations (India) Limited | 249.25 Million INR | 6.155% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | 58.943% |
| Windlas Biotech Limited | 1.29 Billion INR | 81.992% |
| ZIM Laboratories Limited | 253.82 Million INR | 7.848% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 99.457% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 105.684% |
| Divi's Laboratories Limited | 33.08 Billion INR | 99.293% |
| Hester Biosciences Limited | 364.81 Million INR | 35.882% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 91.604% |
| Amrutanjan Health Care Limited | 457.54 Million INR | 48.877% |
| Strides Pharma Science Limited | 5.22 Billion INR | 95.524% |
| Venus Remedies Limited | 534.65 Million INR | 56.25% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 92.522% |
| Nectar Lifesciences Limited | 923.8 Million INR | 74.68% |
| Shilpa Medicare Limited | 1.36 Billion INR | 82.88% |
| Aarti Drugs Limited | 7.14 Billion INR | 96.728% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | 85.351% |
| Suven Life Sciences Limited | -1.22 Billion INR | 119.082% |
| Ind-Swift Limited | 1.22 Billion INR | 80.92% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 98.362% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 106.071% |
| Themis Medicare Limited | 392.58 Million INR | 40.419% |
| Hikal Limited | 32.11 Million INR | -628.462% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 99.077% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | 62.664% |
| Wockhardt Limited | -670 Million INR | 134.912% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 95.492% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -2479.3% |
| Neuland Laboratories Limited | 5.31 Billion INR | 95.602% |
| Morepen Laboratories Limited | 4.17 Billion INR | 94.396% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -12.429% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -751.879% |